CCC Diagnostics, Inc Awarded Qualifying Therapeutic Discovery Project Grant

CCC Diagnostics, Inc. has received a grant of $244,479.25 under the Qualifying Therapeutic Discovery Project created by Congress as a component of the Patient Protection and Affordable Care Act of 2010, signed into law by President Obama on March 23


CCC Diagnostics, Inc. has received a grant of $244,479.25 under the Qualifying Therapeutic Discovery Project created by Congress as a component of the Patient Protection and Affordable Care Act of 2010, signed by President Obama on March 23, 2010. This grant was awarded to further development and commercialization of the DirectHit® Test Panel for Breast Cancer. DirectHit is a vastly improved diagnostic test for breast cancer treatment that accurately predicts the tumor’s response to four commonly prescribed classes of anti-cancer drugs. The DirectHit Test Panel is the only diagnostic test which can predict the responsiveness of breast cancer patients to two classes of chemotherapy drugs, taxanes and capecitabine. In addition, DirectHit is significantly more accurate than existing tests for estrogen receptor and the HER-2/neu. John Hughes, CEO of CCC Diagnostics, commented “ We are very pleased to receive this grant. The funding will allow us to expand the technology of the DirectHit and aid more patients and their physicians in making informed choices about their treatments”.

For mor information visit www.directhittest.com

Company Contact Information
CCC Diagnostics Inc
Scott Deamond
3918 Vero Rd Suite B
Baltimore MD
21227
410-633-4885 x1071

Press Release Distribution and Press Release Service by I-Newswire